ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery

Transfusion
Jérôme LargheroJean-Pierre Marolleau

Abstract

Red cell (RBC) depletion is needed to bypass ABO mismatch in allogeneic bone marrow transplantation (BMT). Technical and clinical data obtained after bone marrow (BM) processing with a continuous-flow cell separator (Cobe Spectra, Gambro BCT) are reported. RBC depletion and recovery of nucleated cells, CD3+ cells, CD34+ cells, and colony-forming unit-granulocyte-macrophage were calculated. Bacteriologic contaminations, side effects of graft infusion, and hematopoietic recovery were analyzed. A total of 114 BM samples were processed. The mean volume collected was 1099 mL (range, 390-2450 mL). Initial and residual mean RBCs volumes were 309.9 and 4.0 mL corresponding to a depletion of 98.6 +/- 0.78 percent. Before processing, the mean numbers of nucleated cells, granulocytes, CD3+ cells, CD34+ cells, and CFU-GM were 20.28 x 10(9), 12.79 x 10(9), 1.96 x 10(9), 356.7 x 10(6), and 195.6 x 10(5), respectively. The mean corresponding recoveries after processing were 33.66, 48.98, 82.02, 82.2, and 93.9 percent. Limited side effects were observed in 14 patients without correlation with residual RBCs volume. All but two patients engrafted. BM processing with the Cobe Spectra cell separator provides high rates of RBC depletion without sig...Continue Reading

References

Jun 1, 1989·Transfusion·C S RosenfeldR K Shadduck
Mar 30, 2000·Journal of Hematotherapy & Stem Cell Research·J González-CamposJ de Luís-Navarro
Mar 22, 2001·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·K TsubakiA Kanamaru
Jul 20, 2002·Bone Marrow Transplantation·G StussiJ D Seebach

❮ Previous
Next ❯

Citations

Nov 27, 2014·Plastic and Reconstructive Surgery. Global Open·Fumio OhnishiKazuo Kishi
Jun 17, 2014·Bone Marrow Transplantation·T LeemhuisM B C Koh
Sep 8, 2011·Bone Marrow Transplantation·S D RowleyP Bhattacharyya
Jan 27, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sibel Akpınar Tekgündüz, Namık Özbek
May 1, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Dobrila VeljkovićZeljko Zečević
Feb 10, 2009·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·S Cappellesso-FleuryP Bourin
Jun 29, 2011·Journal of Clinical Apheresis·V WittG Fritsch
Mar 9, 2011·Transfusion·Jennifer Daniel-Johnson, Joseph Schwartz
Feb 24, 2015·Journal of Biomechanics·Hermann O MayrAnke Bernstein
Oct 6, 2010·Revista latino-americana de enfermagem·Ana Carolina de Jesus Vieira Curcioli, Emilia Campos de Carvalho
Aug 13, 2017·Journal of Translational Medicine·Soo-Zin Kim-WannerHalvard Bonig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Journal of Hematotherapy & Stem Cell Research
J González-CamposJ de Luís-Navarro
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Jörg D SeebachGVHD Working Committee of Center for International Blood and Marrow Transplant Research
© 2021 Meta ULC. All rights reserved